Welcome to our dedicated page for 89Bio news (Ticker: ETNB), a resource for investors and traders seeking the latest updates and insights on 89Bio stock.
89Bio, Inc. (NASDAQ: ETNB) is a clinical-stage biopharmaceutical company pioneering therapies for liver and cardiometabolic diseases, with its lead candidate pegozafermin advancing through Phase 3 trials. This page serves as the authoritative source for all official company updates, including clinical developments, regulatory milestones, and strategic partnerships.
Investors and researchers will find timely updates on-therapeutic progress for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The curated news collection provides essential context on trial designs, scientific publications, and market developments relevant to 89Bio's glycoPEGylated FGF21 analog platform.
All content is rigorously verified to ensure compliance with financial disclosure regulations. Bookmark this page for structured access to 89Bio's progress in addressing critical unmet medical needs through innovative biopharmaceutical research.
89bio, a clinical-stage biopharmaceutical company, will present 48-week data from its Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) at the EASL International Liver Congress in Milan, Italy, from June 5 to 8, 2024. The data highlights pegozafermin as the first FGF21 analog showing positive, sustained benefits over 48 weeks in patients with advanced MASH. The presentation will cover the drug's efficacy, tolerability, and improvements in liver health markers, and will be delivered by Dr. Rohit Loomba on June 8.
89bio has initiated the Phase 3 ENLIGHTEN-Cirrhosis trial for pegozafermin in patients with MASH and compensated cirrhosis (F4). This is the first FGF21 analog to reach this trial stage for this patient subset. The trial will involve 760 patients, assessing fibrosis regression at 24 months, potentially supporting accelerated approval in the U.S. and Europe. The trial's primary goal is to observe clinical outcome events for confirmatory or full approval. The ENLIGHTEN-Cirrhosis trial builds on promising Phase 2b results showing improvements in liver health markers, aiming to meet the urgent need for effective therapies in MASH with compensated cirrhosis.
89bio, Inc. announced the approval of non-qualified stock options for four new employees under the 2023 Inducement Plan. The options allow the purchase of 48,150 shares of the Company's common stock at the closing price on May 6, 2024. The options will vest over a four-year period, contingent on continued employment.
89bio, Inc. (Nasdaq: ETNB) reported its Q1 2024 financial results, highlighting the initiation of Phase 3 trials for pegozafermin in MASH patients, EMA's PRIME status, and positive data from the ENLIVEN Phase 2b Trial. The company also entered a collaboration agreement for commercial supply and appointed a new Board member. Financially, 89bio had $562.3 million in cash, R&D expenses increased to $47.4 million, G&A expenses rose to $9.8 million, resulting in a net loss of $51.7 million.
89bio, Inc. (Nasdaq: ETNB) will participate in the BofA Securities 2024 Health Care Conference to present their innovative therapies for liver and cardiometabolic diseases. The presentation is scheduled for May 15, 2024, at 2:20 PM PDT.
89bio, Inc. (Nasdaq: ETNB) will host a key opinion leader event discussing pegozafermin's potential in advanced metabolic dysfunction-associated steatohepatitis (MASH) on May 16, 2024, featuring expert hepatologist Arun Sanyal, M.D. The webinar will cover the ENLIGHTEN-Cirrhosis trial and the commercial prospects for pegozafermin in advanced MASH.
FAQ
What is the current stock price of 89Bio (ETNB)?
What is the market cap of 89Bio (ETNB)?
